Study Metrics
Total Sample
943
Treatment Group
518
Control Group
425
Covariates
8
PICO Comparisons
1
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Hou |
| Publication Year: | 2022 |
| DOI: | https://doi.org/10.1001/jamanetworkopen.2022.18371 |
| Preprint: | No preprint |
Institution & Funding
| Institutions: | Harvard T. H. Chan School of Public Health, University of British Columbia, Brigham and Women's Hospital/Harvard Medical School, Merck & Co, Inc |
| Funding: | Declared: Public, private |
| Funding Institutions: | The study was supported by Merck & Co, Inc; by grants P30 AR072577 (Dr Liao) and K99NS114850 (Dr Beaulieu-Jones) from the National Institutes of Health (NIH); and grant U01CA209414 from the National Cancer Institute of the NIH (Dr Christiani). |
Study Context
| Disease: | Colorectal Cancer |
| Disease Category: | Oncology |
| Data Type: | Electronic Health Records |
| Number of Data Sources: | 1 |
| Geography: | US |
| Eligible Sample: | 943.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Missing Data Method: | Complete case |
| Matching Method: | PS matching |
| Analysis Method: | Cox PH |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | COST |
| Registration Number: | NCT00002575 |
| Target Trial DOI: | https://doi.org/10.1056/NEJMoa032651 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
5-year overall survival
COST
RD
Efficacy
Population
Adult patients (≥18 years) with early-stage (stages I-III) colon cancer who underwent colectomy
Intervention
Laparoscopy-assisted colectomy (LAC)
Comparison
Open colectomy (OC)
Outcome
5-year overall survival
RCT Result
0.01
95% CI: [-0.17, 0.18]
vs
TTE Result
-0.01
95% CI: [-0.07, 0.06]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Different Direction
Different conclusions
Different conclusions
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | Merck & Co, Inc. |
| Funding Source: | Declared: Public, private |
| Funding Institutions: | The study was supported by Merck & Co, Inc; by grants P30 AR072577 (Dr Liao) and K99NS114850 (Dr Beaulieu-Jones) from the National Institutes of Health (NIH); and grant U01CA209414 from the National Cancer Institute of the NIH (Dr Christiani). |